期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

替吉奥联合奥沙利铂治疗晚期大肠癌的临床观察 被引量：18

下载PDF
导出
摘要 目的观察替吉奥(S-1)联合奥沙利铂治疗晚期大肠癌的疗效和不良反应。方法将45例晚期大肠癌患者随机分为两组。替吉奥联合奥沙利铂方案组23例,予S-180mg/m2,每日分2次口服,dl～d14;奥沙利铂100mg/m2,静脉滴注,d1。21d为1个周期,共4～6个周期。对照组(FOLFOX6方案组)22例,奥沙利铂100mg/m2,静脉滴注2h,dl;亚叶酸钙400mg/m2,静脉滴注2h,dl;5-氟尿嘧啶400mg/m2,静脉注射,d1,然后以2400mg/m2持续静脉泵注46h。2周为1个周期,共6～12个周期。化疗2个周期后评价两组的客观疗效,观察不良反应。结果 45例均可评价疗效。替吉奥联合奥沙利铂方案组的有效率为47.8%,中位进展期(mTTP)为6.3个月;FOLFOX6方案组的有效率为54.5%,mTTP为6.7个月,两组近期有效率的差异无统计学意义(P>0.05)。替吉奥联合奥沙利铂方案组的恶心呕吐反应的发生率明显低于FOLFOX6方案组,差异有统计学意义(P<0.05);其他相关不良反应的发生率亦低于FOLFOX6方案组,但均无统计学意义(P>0.05)。结论替吉奥联合奥沙利铂方案治疗晚期大肠癌与FOLFOX6方案比较,疗效相当,但不良反应较轻,耐受性更好,更适合体质较差的患者。
作者 谢猛 马福 李洪渊
机构地区 安徽省阜阳市第二人民医院肿瘤科
出处 《中国癌症防治杂志》 CAS 2013年第2期159-161,共3页 CHINESE JOURNAL OF ONCOLOGY PREVENTION AND TREATMENT
关键词 大肠肿瘤 替吉奥 奥沙利铂 FOLFOX6 疗效 不良反应
分类号 R735.34 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1Ismaili N. Treatment of colorectal liver metastases[ J ] .World Journalof Surgical Oncology,2011,9: 154.
  • 2Chan K,Chiang JM,Lee CF,et al.Outcomes of resection for col-orectal cancer hepatic metastases stratified by evolving eras of treat-ment[j].World Journal of Surgical 0ncology,2011,9: 174.
  • 3陆红梅,周鲁莲,刘金菊,刘淑红.替吉奥及卡培他滨联合奥沙利铂一线治疗晚期大肠癌的近期疗效比较[J].肿瘤研究与临床,2012,24(9):613-615. 被引量：11
  • 4陈永昌,安欣,张乐,陈翠,徐瑞华,李宇红,王风华.奥沙利铂辅助化疗失败后一线再引入治疗晚期结直肠癌的研究[J].中国肿瘤临床,2012,29(13):927-931. 被引量：13
  • 5Franko J,Shi Q,Goldman CD,et al.Treatment of colorectal peri-toneal carcinomatosis with systemic chemotherapy : a pooled analysisof north central cancer treatment group phase III trials N9741 andN9841 [ J ] Journal of Clinical Oncology, 2012,30( 3) : 263-267.
  • 6Sanoff UK,Carpenter WR, Martin CF,et al.Comparative effective-ness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemother-apy for stage III colon cancer[j].J Natl Cancer Inst,2012,104(3):211-227.
  • 7Zdenkowski N,Chen S,van der Westhuizen A,et al.Curative strate-gies for liver metastases from colorectal cancer:a review [j].The0ncologist,2012,17(2) :201-211.
  • 8Chibaudel B,Toumigand C,Andr6 T,et al.Therapeutic strategy inunresec table metastatic colorectal cancer[ j].Ther Adv Med Oncol,2012,4(2):75-89.

二级参考文献20

  • 1Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. Cancer J Clin, 2010, 60(5): 277-300.
  • 2Maindrault-Goebel F, C.Tournigandl, T. Andreet, et al, Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer[J]. Ann Oncol, 2004, 15(8): 1210-1214.
  • 3Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer[J]. Oncologist, 2007, 12(1):38-50.
  • 4Grothey A. Medical treatment of advanced colorectal cancer in 2009[J]. Ther Adv Med Oncol, 2009, 1(2): 55-68.
  • 5Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741[J].J Clin Oncol, 2008, 26(35): 5721-5727.
  • 6DouillardJY, Gunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial[J]. Lancet, 2000, 355(9209): 1041-1047.
  • 7Tournigand C, Cervantes A, Figer A, et al. OPTIMOXI: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a Stop-and-Go fashion in advanced colorectal cancer-a GERCOR study[J].J Clin Oncol, 2006, 24(3): 394-400.
  • 8Andre T, Tournigand C, Mineur L, et al, Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study[J]. Ann Oncol, 2007, 18(1): 77-81.
  • 9TabemeroJ, E.Aranda, A. Gomez, et al. Phase Ⅲ study of first line XELOX plus bevacizumab(BEV)for 6 cycles followed by XELOX plus BEV or single-agent(s-a)BEV as maintenance therapy in patients(pts)with metastatic coloreetal cancer(mCRC): The MACRO Trial[J].J Clin Oncol, 2010, 28(Suppl 15): 261s(abstract 3501).
  • 10Groth A, Hart L, Rowland KM, et al. Intermittent oxaliplatin(Oxa li) adminstration and time-to-treatment -failure(TTF) in metastatic colorectal cancer(MCRC): final result of the phase Ⅲ concept trail[J]. ASCO meeting Abstracts, 2008, 26: 4010.

共引文献21

同被引文献151

  • 1Caitlin A Schonewolf,Monal Mehta,Devora Schiff,Hao Wu,Bruce G Haffty,Vassiliki Karantza,Salma K Jabbour.Autophagy inhibition by chloroquine sensitizes HT-29 colorectal cancer cells to concurrent chemoradiation[J].World Journal of Gastrointestinal Oncology,2014,6(3):74-82. 被引量：14
  • 2谭纯文,钟献,沈彦伟,袁瑛.奥沙利铂与西妥昔单抗联用的分子机制研究现状[J].肿瘤防治研究,2014,41(2):176-180. 被引量：4
  • 3石昌顺.中药葛根的研究进展[J].中草药,1994,25(9):496-497. 被引量：84
  • 4吕万丽,胡君娥,张艳,王卫锋.大肠癌病人应用奥沙利铂化疗致不良反应的护理[J].护理研究（中旬版）,2007,21(8):2131-2132. 被引量：16
  • 5Toda Y,Machida N,Boku N. The role of oral furopyrimidinesin colorectal cancer treatment-a review[J].Gan To KagakuRyoho,2010,37(7) : 1198-1202.
  • 6Hong YS,Park YS,Lim HY’et al. S-l plus oxaliplatin versuscapecitabine plus oxaliplatin for first-line treatment of pa-tients with metastatic colorectal cancer : a randomized, nonin-feriority phase 3 trial[ J]. Lancet Oncol, 2012,13(11):1125-1132.
  • 7Kweekel D M,Antonini N F,Nortier J W,et al.Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array[J].Br J Cancer,2009,101(2):357-362.
  • 8Becker C,Fantini M C,Wirtz S,et al.IL-6 signaling promotes tumor growth in colorectal cancer[J].Cell Cycle,2005,4(2):217-220.
  • 9Ashizawa T,Okada R,Suzuki Y,et al.Study of interleukin-6 in the spread of colorectal cancer:the diagnostic significance of IL-6[J].Acta Med Okayama,2006,60(6):325-330.
  • 10Kapitanovi?S,?a?ev T,Catela Ivkovi?T,et al.TNFαgene/protein in tumorigenesis of sporadic colon adenocarcinoma[J].Exp Mol Pathol,2014,97(2):285-291.

引证文献18

二级引证文献72

中国癌症防治杂志
2013年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部